<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.biomedcentral.com/feeds/latestarticles/journal?journal=bmcmusculoskeletdisord&amp;quantity=&amp;format=rss&amp;version=">
        <title>BMC Musculoskeletal Disorders - Latest Articles</title>
        <link>http://www.biomedcentral.com/bmcmusculoskeletdisord/</link>
        <description>The latest research articles published by BMC Musculoskeletal Disorders</description>
        <dc:date>2009-11-22T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2474/10/144" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2474/10/143" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2474/10/142" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2474/10/141" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2474/10/140" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2474/10/139" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2474/10/138" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2474/10/137" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2474/10/136" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2474/10/135" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.biomedcentral.com/1471-2474/10/144">
        <title>A prospective study of prognostic factors for duration of sick leave after endoscopic carpal tunnel release</title>
        <description>Background:
Endoscopic carpal tunnel release with a single portal technique has been shown to reduce sick leave compared to open carpal tunnel release, claiming to be a less invasive procedure and reducing scar tenderness leading to a more rapid return to work, and the purpose of this study was to identify prognostic factors for prolonged sick leave after endoscopic carpal tunnel release in a group of employed Danish patients.
Methods:
The design was a prospective study including 75 employed patients with carpal tunnel syndrome operated with ECTR at two hospitals. The mean age was 46 years (SD 10.1), the male/female ratio was 0.42, and the mean preoperative duration of symptoms 10 months (range 6-12). Only 21 (28%) were unable to work preoperatively and mean sick leave was 4 weeks (range 1-4). At base-line and at the 3-month follow-up, a self-administered questionnaire was collected concerning physical, psychological, and social circumstances in relation to the hand problem. Data from a nerve conduction examination were collected at baseline and at the 3-month follow-up. Significant prognostic factors were identified through multiple logistic regression analysis.
Results:
After the operation, the mean functional score was reduced from 2.3 to 1.4 (SD 0.8) and the mean symptom score from 2.9 to 1.5 (SD 0.7). The mean sick leave from work after the operation was 19.8 days (SD 14.3). Eighteen patients (24%) had more than 21 days of sick leave. Two patients (3%) were still unable to work after 3 months. Significant prognostic factors in the multivariate analysis for more than 21 days of postoperative sick leave were preoperative sick leave, blaming oneself for the hand problem and a preoperative distal motor latency.
Conclusion:
Preoperative sick leave, blaming oneself for the hand problem, and a preoperative distal nerve conduction motor latency were prognostic factors for postoperative work absence of more than 21 days. Other factors may be important (clinical, demographic, economic, and workplace) in explaining the great variance in the results of sick leave after carpal tunnel release between studies from different countries.</description>
        <link>http://www.biomedcentral.com/1471-2474/10/144</link>
                <dc:creator>Torben Hansen</dc:creator>
                <dc:creator>Jesper Dalsgaard</dc:creator>
                <dc:creator>Anette Meldgaard</dc:creator>
                <dc:creator>Kristian Larsen</dc:creator>
                <dc:source>BMC Musculoskeletal Disorders 2009, 10:144</dc:source>
        <dc:date>2009-11-22T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2474-10-144</dc:identifier>
        <prism:publicationName>BMC Musculoskeletal Disorders</prism:publicationName>
        <prism:issn>1471-2474</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>144</prism:startingPage>
        <prism:publicationDate>2009-11-22T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2474/10/143">
        <title>Studying the association between musculoskeletal disorders, quality of life and mental health. A primary care pilot study in rural Crete, Greece</title>
        <description>Background:
The burden of musculoskeletal disorders (MSD) on the general health and well-being of the population has been documented in various studies. The objective of this study was to assess the impact of MSD on the quality of life and mental health of patients and to discuss issues concerning care seeking patterns in rural Greece.
Methods:
Patients registered at one rural Primary Care Centre (PCC) in Crete were invited to complete the Nordic Musculoskeletal Questionnaire (NMQ) for the analysis of musculoskeletal symptoms, together with validated instruments for measuring health related quality of life (SF-36) and mental distress (GHQ-28).
Results:
The prevalence rate of MSD was found to be 71.2%, with low back and knee pain being the most common symptoms. Most conditions significantly impaired the quality of life, especially physical dimensions of SF-36. Depression was strongly correlated to most MSD (p&lt;0.001). Multiple logistic analyses revealed that patients who consult general practitioners due to MSD were likely to have more depression or impaired physical functioning compared to those who did not.
Conclusions:
Musculoskeletal disorders were common in patients attending the rural PCC of this study and were associated with a poor quality of life and mental distress that affected their consultation behaviour.</description>
        <link>http://www.biomedcentral.com/1471-2474/10/143</link>
                <dc:creator>Maria Antonopoulou</dc:creator>
                <dc:creator>Athanasios Alegakis</dc:creator>
                <dc:creator>Alexander Hadjipavlou</dc:creator>
                <dc:creator>Christos Lionis</dc:creator>
                <dc:source>BMC Musculoskeletal Disorders 2009, 10:143</dc:source>
        <dc:date>2009-11-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2474-10-143</dc:identifier>
        <prism:publicationName>BMC Musculoskeletal Disorders</prism:publicationName>
        <prism:issn>1471-2474</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>143</prism:startingPage>
        <prism:publicationDate>2009-11-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2474/10/142">
        <title>The expression of Gli3, regulated by HOXD13, may play a role in idiopathic congenital talipes equinovarus </title>
        <description>Background:
Idiopathic congenital talipes equinovarus (ICTEV) is a congenital limb deformity. Based on extended transmission disequilibrium testing, Gli-Kruppel family member 3 (Gli3) has been identified as a candidate gene for ICTEV.  Here, we verify the role of Gli3 in ICTEV development.
Methods:
Using the rat ICTEV model, we analyzed the differences in Gli3 expression levels between model rats and normal control rats. We used luciferase reporter gene assays and ChIP/EMSA assays to analyze the regulatory elements of Gli3.
Results:
Gli3 showed higher expression levels in ICTEV model rats compared to controls (P &lt; 0.05). We identified repressor and activator regions in the rat Gli3 promoter.  The Gli3 promoter also contains two putative Hoxd13 binding sites. Using EMSA, the Hoxd13 binding site 2 was found to directly interact with Hoxd13 in vitro. ChIP assays of the Hoxd13-Gli3 promoter complex from a developing limb confirmed that endogenous Hoxd13 interacts with this region in vivo.
Conclusions:
Our findings suggest that HoxD13 directly interacts with the promoter of Gli3.  The increase of Gli3 expression in ICTEV model animal might result from the low expression of HoxD13.</description>
        <link>http://www.biomedcentral.com/1471-2474/10/142</link>
                <dc:creator>DongHua Cao</dc:creator>
                <dc:creator>ChunLian Jin</dc:creator>
                <dc:creator>MeiHong Ren</dc:creator>
                <dc:creator>ChangKun Lin</dc:creator>
                <dc:creator>Xuan Zhang</dc:creator>
                <dc:creator>Ning Zhao</dc:creator>
                <dc:source>BMC Musculoskeletal Disorders 2009, 10:142</dc:source>
        <dc:date>2009-11-19T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2474-10-142</dc:identifier>
        <prism:publicationName>BMC Musculoskeletal Disorders</prism:publicationName>
        <prism:issn>1471-2474</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>142</prism:startingPage>
        <prism:publicationDate>2009-11-19T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2474/10/141">
        <title>Functional activation of proline-rich tyrosine kinase2 (PYK2) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus</title>
        <description>Background:
Systemic lupus erythematosus (SLE) is a representative systemic autoimmune disease characterized by activated T cells and polyclonally activated B cells that produce autoantibodies. Activation of autoreactive T and B cells plays a pivotal role in the pathogenesis of this disease.A role of focal adhesion kinase (FAK) in the pathogenesis has been suggested. Proline-rich tyrosine kinase2 (PYK2) is structurally related to FAK,however, the functional activation of PYK2 in SLE remains unclear. In the present study, we showed that PYK2 is significantly increased and activated in peripheral blood mononuclear cells (PBMCs) of patients with SLE. In addition, we showed the involvement of PYK2 proteins in the up-regulation of CD40L and CTLA4 expression and PBMC proliferation.MethodFreshly isolated PBMCs from 36 SLE patients, 19 patients with rheumatoid arthritis(RA) and 15 healthy individuals were analyzed for the expression and activation of PYK2 by western-blotting and immunocytochemistry. The other isolated PBMCs from patients with this condition were cultured and stimulated with PMA or TyrA9,and then the expression of costimulatory molecules CD40L and CTLA4 was evaluated using flow cytometry,PBMCs proliferation was determined with [3H]-thymidine incorporation (CPM).Result: Compared with RA patients and healthy donors,PBMCs from SLE patients expressed more of both the total PYK2 protein and its activated/phosphorylated form. The increase of activated PYK2 protein in SLE PBMCs was correlated with the complication of nephritis and inversly associated the level of serum complements. In active SLE patients, activation of PYK2 in PBMCs is accompanying the increased cell proliferation and the induced expression of costimulatory molecules CD40L and CTLA4.
Conclusion:
Our findings indicate that phosphorylated PYK2 in SLE PBMCs may induce the expression of CD40L and CTLA4, and subsequently the cell proliferation. PYK2 signaling enhances the autoreactive lymphocyte activation and plays an important role in the pathogenesis of SLE.</description>
        <link>http://www.biomedcentral.com/1471-2474/10/141</link>
                <dc:creator>Meiying Wang</dc:creator>
                <dc:creator>Hongsheng Sun</dc:creator>
                <dc:creator>Wei Zhang</dc:creator>
                <dc:creator>Yuanchao Zhang</dc:creator>
                <dc:source>BMC Musculoskeletal Disorders 2009, 10:141</dc:source>
        <dc:date>2009-11-17T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2474-10-141</dc:identifier>
        <prism:publicationName>BMC Musculoskeletal Disorders</prism:publicationName>
        <prism:issn>1471-2474</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>141</prism:startingPage>
        <prism:publicationDate>2009-11-17T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2474/10/140">
        <title>Protocol for the ProFHER (PROximal Fracture of the Humerus: Evaluation by Randomisation) trial: a pragmatic multi-centre randomised controlled trial of surgical versus non-surgical treatment for proximal fracture of the humerus in adults</title>
        <description>Background:
Proximal humeral fractures, which occur mainly in older adults, account for approximately 4 to 5% of all fractures. Approximately 40% of these fractures are displaced fractures involving the surgical neck. Management of this group of fractures is often challenging and the outcome is frequently unsatisfactory. In particular it is not clear whether surgery gives better outcomes than non-surgical management. Currently there is much variation in the use of surgery and a lack of good quality evidence to inform this decision.Methods/DesignWe aim to undertake a pragmatic UK-based multi-centre randomised controlled trial evaluating the effectiveness and cost-effectiveness of surgical versus standard non-surgical treatment for adults with an acute closed displaced fracture of the proximal humerus with involvement of the surgical neck. The choice of surgical intervention is left to the surgeon, who must use techniques that they are fully experienced with. This will avoid &apos;learning curve&apos; problems. We will promote good standards of non-surgical care, similarly insisting on care-provider competence, and emphasize the need for comparable provision of rehabilitation for both groups of patients.We aim to recruit 250 patients from a minimum of 18 NHS trauma centres throughout the UK. These patients will be followed-up for 2 years. The primary outcome is the Oxford Shoulder Score, which will be collected via questionnaires completed by the trial participants at 6, 12 and 24 months. This is a 12-item condition-specific questionnaire providing a total score based on the person&apos;s subjective assessment of pain and activities of daily living impairment. We will also collect data for other outcomes, including general health measures and complications, and for an economic evaluation. Additionally, we plan a systematic collection of reasons for non-inclusion of eligible patients who were not recruited into the trial, and their baseline characteristics, treatment preferences and intended treatment.DiscussionThis article presents the protocol for a multi-centre randomised controlled trial. It gives extensive details of, and the basis for, the chosen methods, and describes the key measures taken to avoid bias and to ensure validity.Trial RegistrationCurrent Controlled Trials ISRCTN50850043</description>
        <link>http://www.biomedcentral.com/1471-2474/10/140</link>
                <dc:creator>Helen Handoll</dc:creator>
                <dc:creator>Stephen Brealey</dc:creator>
                <dc:creator>Amar Rangan</dc:creator>
                <dc:creator>David Torgerson</dc:creator>
                <dc:creator>Laura Dennis</dc:creator>
                <dc:creator>Alison Armstrong</dc:creator>
                <dc:creator>Ling-Hsiang Chuang</dc:creator>
                <dc:creator>Ben Cross</dc:creator>
                <dc:creator>Jo Dumville</dc:creator>
                <dc:creator>Sarah Gardner</dc:creator>
                <dc:creator>Lorna Goodchild</dc:creator>
                <dc:creator>Sharon Hamilton</dc:creator>
                <dc:creator>Catherine Hewitt</dc:creator>
                <dc:creator>Rajan Madhok</dc:creator>
                <dc:creator>Nicola Maffulli</dc:creator>
                <dc:creator>Lucy Micklewright</dc:creator>
                <dc:creator>Valerie Wadsworth</dc:creator>
                <dc:creator>Angus Wallace</dc:creator>
                <dc:creator>John Williams</dc:creator>
                <dc:creator>Gill Worthy</dc:creator>
                <dc:source>BMC Musculoskeletal Disorders 2009, 10:140</dc:source>
        <dc:date>2009-11-16T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2474-10-140</dc:identifier>
        <prism:publicationName>BMC Musculoskeletal Disorders</prism:publicationName>
        <prism:issn>1471-2474</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>140</prism:startingPage>
        <prism:publicationDate>2009-11-16T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2474/10/139">
        <title>Expectations, perceptions, and physiotherapy predict prolonged sick leave in subacute low back pain   </title>
        <description>Background:
Brief intervention programs for subacute low back pain (LBP) result in significant reduction of sick leave compared to treatment as usual. Although effective, a substantial proportion of the patients do not return to work. This study investigates predictors of return to work in LBP patients participating in a randomized controlled trial comparing a brief intervention program (BI) with BI and physical exercise.
Methods:
Predictors for not returning to work was examined in 246 patients sick listed 8-12 weeks for low back pain. The patients had participated in a randomized controlled trial, with BI (n = 122) and BI + physical exercise (n = 124). There were no significant differences between the two intervention groups on return to work. The groups were therefore merged in the analyses of predictors. Multiple logistic regression analysis was used to identify predictors for non return to work at 3, 12, and 24 months of follow-up.
Results:
At 3 months of follow-up, the strongest predictors for not returning to work were pain intensity while resting (OR = 5.6; CI = 1.7-19), the perception of constant back strain when working (OR = 4.1; CI = 1.5-12), negative expectations for return to work (OR = 4.2; CI = 1.7-10), and having been to a physiotherapist prior to participation in the trial (OR = 3.3; CI = 1.3-8.3). At 12 months, perceived reduced ability to walk far due to the complaints (OR = 2.6; CI = 1.3-5.4), pain during activities (OR = 2.4; CI = 1.1-5.1), and having been to a physiotherapist prior to participation in the trial (OR = 2.1; CI = 1.1-4.3) were the strongest predictors for non return to work. At 24 months age below 41 years (OR = 2.9; CI = 1.4-6.0) was the only significant predictor for non return to work.
Conclusion:
It appears that return to work is highly dependant on individual and cognitive factors. Patients not returning to work after the interventions were characterized by negative expectations, perceptions about pain and disability, and previous physiotherapy treatment. This is the first study reporting that previous treatment by physiotherapists is a risk factor for long-term sick leave. This has not been reported before and is an interesting finding that deserves more scrutiny.</description>
        <link>http://www.biomedcentral.com/1471-2474/10/139</link>
                <dc:creator>Silje Reme</dc:creator>
                <dc:creator>Eli Hagen</dc:creator>
                <dc:creator>Hege Eriksen</dc:creator>
                <dc:source>BMC Musculoskeletal Disorders 2009, 10:139</dc:source>
        <dc:date>2009-11-13T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2474-10-139</dc:identifier>
        <prism:publicationName>BMC Musculoskeletal Disorders</prism:publicationName>
        <prism:issn>1471-2474</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>139</prism:startingPage>
        <prism:publicationDate>2009-11-13T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2474/10/138">
        <title>Time-course of exercise and its association with 12-month bone changes</title>
        <description>Background:
Exercise has been shown to have positive effects on bone density and strength. However, knowledge of the time-course of exercise and bone changes is scarce due to lack of methods to quantify and qualify daily physical activity in long-term. The aim was to evaluate the association between exercise intensity at 3, 6 and 12 month intervals and 12-month changes in upper femur areal bone mineral density (aBMD) and mid-femur geometry in healthy premenopausal women.
Methods:
Physical activity was continuously assessed with a waist-worn accelerometer in 35 healthy women (35-40 years) participating in progressive high-impact training. To describe exercise intensity, individual average daily numbers of impacts were calculated at five acceleration levels (range 0.3-9.2g) during time intervals of 0-3, 0-6, and 0-12 months. Proximal femur aBMD was measured with dual x-ray absorptiometry and mid-femur geometry was evaluated with quantitative computed tomography at the baseline and after 12 months. Physical activity data were correlated with yearly changes in bone density and geometry, and adjusted for confounding factors and impacts at later months of the trial using multivariate analysis.
Results:
Femoral neck aBMD changes were significantly correlated with 6 and 12 months&apos; impact activity at high intensity levels (&gt;3.9g, r being up to 0.42). Trochanteric aBMD changes were associated even with first three months of exercise exceeding 1.1g (r=0.39-0.59, p&lt;0.05). Similarly, mid-femoral cortical bone geometry changes were related to even first three months&apos; activity (r=0.38-0.52, p&lt;0.05). In multivariate analysis, 0-3 months&apos; activity did not correlate with bone change at any site after adjusting for impacts at later months. Instead, 0-6 months&apos; impacts were significant correlates of 12-month changes in femoral neck and trochanter aBMD, mid-femur bone circumference and cortical bone attenuation even after adjustment. No significant correlations were found at the proximal or distal tibia.
Conclusions:
The number of high acceleration impacts during 6 months of training was positively associated with 12-month bone changes at the femoral neck, trochanter and mid-femur. These results can be utilized when designing feasible training programs to prevent bone loss in premenopausal women.Trial registrationClinical trials.gov NCT00697957</description>
        <link>http://www.biomedcentral.com/1471-2474/10/138</link>
                <dc:creator>Riikka Ahola</dc:creator>
                <dc:creator>Raija Korpelainen</dc:creator>
                <dc:creator>Aki Vainionpaa</dc:creator>
                <dc:creator>Juhani Leppaluoto</dc:creator>
                <dc:creator>Timo Jamsa</dc:creator>
                <dc:source>BMC Musculoskeletal Disorders 2009, 10:138</dc:source>
        <dc:date>2009-11-12T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2474-10-138</dc:identifier>
        <prism:publicationName>BMC Musculoskeletal Disorders</prism:publicationName>
        <prism:issn>1471-2474</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>138</prism:startingPage>
        <prism:publicationDate>2009-11-12T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2474/10/137">
        <title>Patterns of analgesic use, pain and self-efficacy:          a cross-sectional study of patients attending a hospital rheumatology clinic  </title>
        <description>Background:
Many people attending rheumatology clinics use analgesics and non-steroidal anti-inflammatories for persistent musculoskeletal pain. Guidelines for pain management recommend regular and pre-emptive use of analgesics to reduce the impact of pain. Clinical experience indicates that analgesics are often not used in this way. Studies exploring use of analgesics in arthritis have historically measured adherence to such medication. Here we examine patterns of analgesic use and their relationships to pain, self-efficacy and demographic factors.
Methods:
Consecutive patients were approached in a hospital rheumatology out-patient clinic. Pattern of analgesic use was assessed by response to statements such as &apos;I always take my tablets every day.&apos; Pain and self-efficacy (SE) were measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Arthritis Self-Efficacy Scale (ASES). Influence of factors on pain level and regularity of analgesic use were investigated using linear regression. Differences in pain between those agreeing and disagreeing with statements regarding analgesic use were assessed using t-tests.
Results:
218 patients (85% of attendees) completed the study. Six (2.8%) patients reported no current pain, 26 (12.3%) slight, 100 (47.4%) moderate, 62 (29.4%) severe and 17 (8.1%) extreme pain. In multiple linear regression self efficacy and regularity of analgesic use were significant (p &lt; 0.01) with lower self efficacy and more regular use of analgesics associated with more pain.Low SE was associated with greater pain: 40 (41.7%) people with low SE reported severe pain versus 22 (18.3%) people with high SE, p &lt; 0.001. Patients in greater pain were significantly more likely to take analgesics regularly; 13 (77%) of those in extreme pain reported always taking their analgesics every day, versus 9 (35%) in slight pain. Many patients, including 46% of those in severe pain, adjusted analgesic use to current pain level. In simple linear regression, pain was the only variable significantly associated with regularity of analgesic use: higher levels of pain corresponded to more regular analgesic use (p = 0.003).
Conclusion:
Our study confirms that there is a strong inverse relationship between self-efficacy and pain severity. Analgesics are often used irregularly by people with arthritis, including some reporting severe pain.</description>
        <link>http://www.biomedcentral.com/1471-2474/10/137</link>
                <dc:creator>Ruth Blamey</dc:creator>
                <dc:creator>Kate Jolly</dc:creator>
                <dc:creator>Sheila Greenfield</dc:creator>
                <dc:creator>Paresh Jobanputra</dc:creator>
                <dc:source>BMC Musculoskeletal Disorders 2009, 10:137</dc:source>
        <dc:date>2009-11-10T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2474-10-137</dc:identifier>
        <prism:publicationName>BMC Musculoskeletal Disorders</prism:publicationName>
        <prism:issn>1471-2474</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>137</prism:startingPage>
        <prism:publicationDate>2009-11-10T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2474/10/136">
        <title>Does physical activity change predict functional recovery in low back pain? Protocol for a prospective cohort study 

</title>
        <description>Background:
Activity advice and prescription are commonly used in the management of low back pain (LBP). Although there is evidence for advising patients with LBP to remain active, facilitating both recovery and return to work, to date no research has assessed whether objective measurements of free living physical activity (PA) can predict outcome, recovery and course of LBP.
Methods:
An observational longitudinal study will investigate PA levels in a cohort of community-dwelling working age adults with acute and sub-acute LBP. Each participant&apos;s PA level, functional status, mood, fear avoidance behaviours, and levels of pain, psychological distress and occupational activity will be measured on three occasions during for 1 week periods at baseline, 3 months, and 1 year. Physical activity levels will be measured by self report, RT3 triaxial accelerometer, and activity recall questionnaires. The primary outcome measure of functional recovery will be the Roland Morris Disability Questionnaire (RMDQ). Free living PA levels and changes in functional status will be quantified in order to look at predictive relationships between levels and changes in free living PA and functional recovery in a LBP population.DiscussionThis research will investigate levels and changes in activity levels of an acute LBP cohort and the predictive relationship to LBP recovery. The results will assess whether occupational, psychological and behavioural factors affect the relationship between free living PA and LBP recovery. Results from this research will help to determine the strength of evidence supporting international guidelines that recommend restoration of normal activity in managing LBP.Trial registration[Clinical Trial Registration Number, ACTRN12609000282280]</description>
        <link>http://www.biomedcentral.com/1471-2474/10/136</link>
                <dc:creator>Paul Hendrick</dc:creator>
                <dc:creator>Stephan Milosavljevic</dc:creator>
                <dc:creator>Melanie Bell</dc:creator>
                <dc:creator>Leigh Hale</dc:creator>
                <dc:creator>Deirdre Hurley</dc:creator>
                <dc:creator>Suzanne McDonough</dc:creator>
                <dc:creator>Markus Melloh</dc:creator>
                <dc:creator>David Baxter</dc:creator>
                <dc:source>BMC Musculoskeletal Disorders 2009, 10:136</dc:source>
        <dc:date>2009-11-06T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2474-10-136</dc:identifier>
        <prism:publicationName>BMC Musculoskeletal Disorders</prism:publicationName>
        <prism:issn>1471-2474</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>136</prism:startingPage>
        <prism:publicationDate>2009-11-06T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2474/10/135">
        <title>Health-related quality of life after vertebral or hip fracture: a seven-year follow-up study</title>
        <description>Background:
The negative impact of vertebral and hip low-energy fractures on health-related quality-of-life (HRQOL) has been demonstrated previously, but few prospective long-term follow-up studies have been conducted. This study aims to (i) investigate the changes and long-term impact of vertebral or hip fracture and between fracture groups on HRQOL in postmenopausal women prospectively between two and seven years after the inclusion fracture, (ii) compare HRQOL results between fracture and reference groups and (iii) study the relationship between HRQOL and physical performance, spinal deformity index and bone mineral density at seven-year follow-up.
Methods:
Ninety-one women examined two years after a low-energy vertebral or hip fracture were invited to a new examination seven years after the diagnosis. HRQOL was examined using the SF-36 questionnaire and was compared with an age and sex-matched reference group. Physical function was assessed using tests and questionnaires. Bone mineral density was measured. Radiographs of the spine were evaluated using the visual semiquantitative technique. A longitudinal and cross-sectional design was used in this study. Statistical analyses included descriptive statistics, Student&apos;s t-tests, ANCOVA, and partial correlation.
Results:
Sixty-seven women participated. In the 42 women (mean age 75.8, SD 4.7) with vertebral fracture as inclusion fracture, bodily pain had deteriorated between two and seven years and might be explained by new fracture. Remaining pronounced reduction of HRQOL was seen in all domains except general health and mental health at seven-year follow-up in women with vertebral fractures compared to the reference group (p &lt; 0.05). All 25 women (mean age 75.0, SD 4.7) with hip fracture as inclusion fracture had no significant changes in HRQOL between two and seven years and did not differ from the reference group regarding HRQOL after seven years. The vertebral group had significantly lower values for bodily pain, vitality, role-emotional function and mental health compared to the hip group. HRQOL showed a positive relationship between physical activity, static balance and handgrip strength.
Conclusion:
The long-term reduction of HRQOL in women with vertebral fracture emerged clearly in this study. The relationships between HRQOL and physical performance in women with vertebral and hip fracture raise questions for more research.</description>
        <link>http://www.biomedcentral.com/1471-2474/10/135</link>
                <dc:creator>Inger Hallberg</dc:creator>
                <dc:creator>Margareta Bachrach-Lindstrom</dc:creator>
                <dc:creator>Staffan Hammerby</dc:creator>
                <dc:creator>Goran Toss</dc:creator>
                <dc:creator>Anna-Christina Ek</dc:creator>
                <dc:source>BMC Musculoskeletal Disorders 2009, 10:135</dc:source>
        <dc:date>2009-11-03T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2474-10-135</dc:identifier>
        <prism:publicationName>BMC Musculoskeletal Disorders</prism:publicationName>
        <prism:issn>1471-2474</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>135</prism:startingPage>
        <prism:publicationDate>2009-11-03T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
